Par claims patent win in dispute over pain drug
WOODCLIFF LAKE, N.J. — Generic drug developer Par Pharmaceutical Companies Inc. said Monday a federal court in Delaware ruled in the company’s favor in a patent dispute over the pain drug Ultram ER.
The company wants to sell generic versions of the extended-release drug, which is also known as tramadol. Purdue Pharma LP is the patent holder, while Biovail Corp. and a division of Johnson & Johnson collaborate in selling the drug.
Par said it has tentative approval from the U.S. Food and Drug Administration for the 100mg and 200mg strength versions of tramadol ER.
In a separate statement, Canadian drug developer Biovail said the decision could affect its revenue if Par decides to launch generic versions of Ultram ER. Biovail said it recorded $81.9 million in revenue from Ultram ER in 2008.
Shares of Par rose 71 cents, or 4 percent, to $18 in morning trading. Shares of Biovail fell 49 cents, or 3.5 percent, to $13.40.
Filed under Intellectual Property, News | Tags: Diagnosis And Treatment, Health Care Industry, Medication, New Jersey, North America, Ownership Changes, United States, Woodcliff Lake | Comment Below
Related?
Par ticks up, having gained 14 percent on Ultram patent ruling and generic Catapres approvalAugust 21st, 2009 Par Pharma edges higher to finish weekly gainsNEW YORK — Shares of Par Pharmaceutical Cos. continued to rise Friday, capping a week where the company won a patent challenge that could allow it to start selling a generic version of a pain drug, and won FDA approval of a generic blood pressure patch.
Dish prevails over TiVo in initial patent ruling over time-warp technologyAugust 5th, 2009 Dish prevails over TiVo in initial patent rulingENGLEWOOD, Colo. — Dish Network Corp.
Patent ruling on Lilly drug stirs some surprise but little reaction from investorsAugust 18th, 2009 Patent ruling on Lilly drug stirs some surpriseINDIANAPOLIS — A federal court ruling that invalidated a patent protecting Eli Lilly and Co.'s cancer drug Gemzar surprised at least one analyst covering the company but stirred little reaction from investors in trading Tuesday. Lilly said Monday evening the U.S.
InterDigital shares plunge after ITC rules for Nokia in patent disputeAugust 17th, 2009 Ahead of the Bell: InterDigital shares plungeNEW YORK — InterDigital Inc. shares dove in premarket trading Monday after a U.S.
Drug wholesalers and insurers sue Merck, saying Singulair patent is invalid and inflates priceAugust 14th, 2009 Merck sued over patent on allergy drug SingulairNEW YORK — The battle over the patent on Merck and Co.'s allergy and asthma drug Singulair, the best-selling drug of one of the world's largest drug makers, continued Friday as a group of drug distributors and health insurers sued Merck. The filers say Merck should never have been awarded one of the key patents supporting the drug, and that is has wrongfully intimidated rivals by suing them for patent infringement, which has kept competing versions of Singulair off the U.S.
Judge upholds Merck patent on blockbuster allergy drug Singulair, protecting sales till 2012August 19th, 2009 Judge rules for Merck on allergy drug's patentWHITEHOUSE STATION, N.J. — A federal judge in New Jersey rules in favor of drugmaker Merck in a patent fight with a company wanting to make a generic version of Merck's top-selling drug.
$150 Million Class Action Settlement by Three Drug MakersSeptember 21st, 2006 The nationalwide class action lawsuit, which accused TAP Pharmaceutical Products Inc., Abbott Laboratories and Takeda Pharmaceutical Co. Ltd., three drug makers of overcharging consumers for the prescription drug Lupron, wasb settled for $150 million.
KV Pharmaceutical faces lawsuit December 4th, 2008 KV Pharmaceutical Co. faces class action lawsuit from its own shareholders.
